Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.69 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | RHOC | P08134 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.69 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.67 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.63 |
| ▸ | PDE6D | O43924 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27925208 | 0.94 | HMGCR (0.67) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13847793 | 0.91 | HMGCR (0.59) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12073345 | 0.89 | HMGCR (0.72) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12192335 | 0.88 | HMGCR (0.77) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5809239 | 0.88 | HMGCR (0.71) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL28543389 | 0.87 | HMGCR (0.63) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5806847 | 0.87 | HMGCR (0.70) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5809438 | 0.87 | HMGCR (0.70) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL10054698 | 0.87 | HMGCR (0.69) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14318919 | 0.86 | HMGCR (0.69) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194867-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES | APOTEX PHARMACHEM INC. | 2006-08-31 | — | — | US | claimed |
| US-8124790-B2 | Preparation process useful in synthesis of atorvastatin | MEDICHEM KOREA CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO., LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| US-7812179-B2 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2010-10-12 | — | — | US | disclosed |
| US-7812179-B2 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2010-10-12 | — | — | US | disclosed |
| US-7812179-B2 | Process for the preparation of atorvastatin and intermediates | APOTEX PHARMACHEM INC. (CA) | 2010-10-12 | — | — | US | disclosed |
| US-7615647-B2 | Process for producing atorvastatin hemicalcium | APOTEX PHARMACHEM INC. (CA) | 2009-11-10 | — | — | US | disclosed |
| US-7615647-B2 | Process for producing atorvastatin hemicalcium | APOTEX PHARMACHEM INC. (CA) | 2009-11-10 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-5280126-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1994-01-18 | — | — | US | disclosed |
| US-5273995-A | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | WARNER-LAMBERT COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| US-5245047-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| US-5216174-A | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT CO. (US) | 1993-06-01 | — | — | US | disclosed |
| US-5149837-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-09-22 | — | — | US | disclosed |
| US-5124482-A | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-06-23 | — | — | US | disclosed |
| US-5097045-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| US-5003080-A | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0330172-A2 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4681893-A | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | HMGCR, DHCR7, LIPA | HMGCR 1/4885SLCO1B1 776/4885ABCB11 1251/4885 |
| US-20060194867-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES | ACSL1, ACSL3, ACSL6 | HMGCR 5/4885SLCO1B1 685/4885ABCB11 1442/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | HMGCR 105/4885SLCO1B1 664/4885ABCB11 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.